Literature DB >> 11228364

Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells.

M A Conway1, L Madrigal-Estebas, S McClean, D J Brayden, K H Mills.   

Abstract

The immunogenicity and protective efficacy of systemically and orally delivered pertussis antigens entrapped in either microparticle poly-lactide-co-glycolide (PLG) or nanoparticle PLG formulations were evaluated in a murine respiratory challenge model for infection with Bordetella pertussis. The results demonstrate that immunization with two parenteral doses of 1 microg or three oral doses of 100 microg of pertussis toxoid (PTd) and filamentous haemagglutinin (FHA) encapsulated in PLG conferred a high level of protection against B. pertussis challenge. Furthermore protection could be generated with a single parenteral immunization with a combined microparticle and nanoparticle formulation. However, the route of immunization and the size of the particles affected the type of T cell response induced. Parenteral immunization with PTd and FHA entrapped in PLG microparticles elicits a potent type 1 T cell response and potent antibody response when given by the intraperitoneal (i.p.) or intramuscular (i.m.) route. In contrast, nanoparticle formulations favoured the induction of Th2 cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11228364     DOI: 10.1016/s0264-410x(00)00433-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

Review 1.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

Review 2.  Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles.

Authors:  José M Morachis; Enas A Mahmoud; Adah Almutairi
Journal:  Pharmacol Rev       Date:  2012-04-27       Impact factor: 25.468

Review 3.  Peptide/protein vaccine delivery system based on PLGA particles.

Authors:  Mojgan Allahyari; Elham Mohit
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

Review 4.  Past, present, and future technologies for oral delivery of therapeutic proteins.

Authors:  Rajesh Singh; Shailesh Singh; James W Lillard
Journal:  J Pharm Sci       Date:  2008-07       Impact factor: 3.534

5.  On technological and immunological benefits of multivalent single-injection microsphere vaccines.

Authors:  Gérard Boehm; Marisa Peyre; Dorothea Sesardic; Rachel J Huskisson; Fatme Mawas; Alexandra Douglas; Dorothy Xing; Hans P Merkle; Bruno Gander; Pål Johansen
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

Review 6.  Cytokines as biomarkers of nanoparticle immunotoxicity.

Authors:  Mahmoud Elsabahy; Karen L Wooley
Journal:  Chem Soc Rev       Date:  2013-06-21       Impact factor: 54.564

Review 7.  Scale of health: indices of safety and efficacy in the evolving environment of large biological datasets.

Authors:  Christie M Sayes; Herman Staats; Anthony J Hickey
Journal:  Pharm Res       Date:  2014-06-12       Impact factor: 4.200

Review 8.  Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.

Authors:  Dorji Dorji; Frits Mooi; Osvaldo Yantorno; Rajendar Deora; Ross M Graham; Trilochan K Mukkur
Journal:  Med Microbiol Immunol       Date:  2017-11-21       Impact factor: 3.402

9.  Biodegradable particles as vaccine delivery systems: size matters.

Authors:  Vijaya B Joshi; Sean M Geary; Aliasger K Salem
Journal:  AAPS J       Date:  2012-10-10       Impact factor: 4.009

10.  Combination antiretroviral drugs in PLGA nanoparticle for HIV-1.

Authors:  Christopher J Destache; Todd Belgum; Keith Christensen; Annemarie Shibata; Akhilesh Sharma; Alekha Dash
Journal:  BMC Infect Dis       Date:  2009-12-09       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.